Business Wire

Ricardo Commissioned to Define a Single Harmonised European Life Cycle Assessment Standard for Zero Emission Vehicles and Batteries

15.2.2023 03:01:00 EET | Business Wire | Press release

Share

Ricardo, a global strategic environmental and engineering consulting company, has commenced a European Union-funded project to develop a baseline for a European-wide commonly accepted and applied single life cycle assessment (LCA) approach for zero emission vehicles (ZEV) and batteries based on evidence and real-world data. This initiative is a Coordination and Support Action supported under the Horizon Europe Framework Programme and has also received funding from UK Research and Innovation (UKRI).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230214005551/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Electric car and truck charging (Photo: Business Wire)

Currently, there is no agreed European or international standard on vehicle life cycle assessment, although there are a number of standards in draft or being developed for electric vehicle (EV) batteries. Defining a single, harmonised life cycle assessment approach for vehicles and batteries is key to providing transparency and comparability of impacts from these products. This will help to achieve Green Deal targets, making Europe the first digitally enabled circular, climate-neutral and sustainable economy. Harmonised standards will facilitate industry, mobility providers and planners to develop sustainable road transport products that are optimised to combat climate change. Ricardo is on the core team of the collaborative TranSensus LCA consortium – jointly coordinated by the Fraunhofer Institute for Structural Durability and System Reliability LBF and the Fraunhofer-Institution of Surface Engineering and Thin Films IST– which comprises 44 stakeholders from industry and research along the full value chain of zero emission vehicles and batteries including: research institutions, vehicle and battery manufacturers, the supply industry, energy providers and recyclers.

Nikolas Hill, Head of Vehicle Technologies and Fuels in Ricardo’s Sustainable Transport team said: “The major report on life cycle impacts of road vehicles that Ricardo undertook for the European Commission in 2020 highlighted the importance of life cycle assessment in sustainable product and business development, but also the challenges for its application. In particular, efforts fully to use and realise the benefits from life cycle assessment approaches by the transport sector are being hampered because there is not an official European standard for vehicle LCA. This is largely because of a lack of a consistent, fair framework or harmonised methodology, plus limitations in accessing and managing real-world data and applying consistent modelling. Through our work with our industry and research partners on this project, Ricardo policy, strategy and technology experts will help to deliver a standard, trustworthy and consistent assessment of full vehicular environmental footprints, to support organisations across the transport value chain progress their objective of achieving climate neutrality.”

Ricardo’s 2020 report for the European Commission, DG Climate Action: Determining the environmental impacts of conventionally and alternatively fuelled vehicles through LCA was the broadest and most comprehensive study of its kind to date. The report assessed the life cycle impacts of 65 different European light- and heavy-duty vehicle types and powertrain combinations. It considered the production of 60 fuel chains for conventional and alternative fuels as well as 14 different forms of electricity generation, the impacts of vehicle (and battery) manufacturing, and vehicle use and maintenance including different ‘end of life’ scenarios. The report also highlighted the positive impact of existing European Union policy in directly supporting the move to a more circular economy and the initiatives aimed at developing a sustainable value chain for hybrid and fully electric vehicles and their batteries in driving down industrial emissions and improving resource efficiency.

Ends

Notes to editors:

TranSensus LCA is funded by the European Union under the Grant Agreement #101056715. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or CINEA. Neither the European Union nor the granting authority can be held responsible for them.

About Ricardo

Ricardo plc is a global strategic, environmental, and engineering consulting company, listed on the London Stock Exchange. With over 100 years of engineering excellence and employing close to 3,000 employees in more than 20 countries, we provide exceptional levels of expertise in delivering leading-edge and innovative cross-sector sustainable products and solutions. Every day, we enable our customers to solve the most complex and dynamic challenges to help achieve a safe and sustainable world. Visit www.ricardo.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Kathryn Bellamy
Group Senior Communications Manager
Ricardo plc
Email: kathryn.bellamy@ricardo.com
Telephone: +44(0)7921 941824

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye